Table 2.
Data Availability Metrics
| Parameter | Overall (N = 230) | GL (n = 81) | PL (n = 149) |
|---|---|---|---|
| Number of medical evaluations, n (%) | |||
| ≥3 | 198 (86.1) | 72 (88.9) | 126 (84.6) |
| <3 | 32 (13.9) | 9 (11.1) | 23 (15.4) |
| Survival status available at last observation date, n (%) | 198 (86.1) | 64 (79.0) | 134 (89.9) |
| Physical characteristics data available at last observation date, n (%) | |||
| Acanthosis nigricans | 186 (80.9) | 72 (88.9) | 114 (76.5) |
| Acromegaloid features | 149 (64.8) | 64 (79.0) | 85 (57.0) |
| Lack of fat in face | 190 (82.6) | 70 (86.4) | 120 (80.5) |
| Muscular appearance | 205 (89.1) | 77 (95.1) | 128 (85.9) |
| Prominent veins | 149 (64.8) | 59 (72.8) | 90 (60.4) |
| Splenomegaly | 168 (73.0) | 62 (76.5) | 106 (71.1) |
| One or more laboratory value measurements available over entire observation period, n (%) | |||
| HbA1c | 200 (87.0) | 67 (82.7) | 133 (89.3) |
| Tg | 225 (97.8) | 79 (97.5) | 146 (98.0) |
| ALT | 221 (96.1) | 77 (95.1) | 144 (96.6) |
| AST | 211 (91.7) | 76 (93.8) | 135 (90.6) |
| Medication use data at baseline available, n (%) | 89 (38.7) | 30 (37.0) | 59 (39.6) |
Abbreviation: Tg, triglycerides.